Professor of Medicine and Rheumatology
University of Glasgow
Glasgow, United Kingdom
Iain McInnes is a global leader in the field of arthritis research. He is Vice Principal and Head of College of Medical Veterinary and Life Sciences and Muirhead Professor of Medicine and Versus Arthritis Professor of Rheumatology in the University of Glasgow. He has led numerous international clinical trials and pathogenesis investigation programmes in inflammatory arthritis. He is Director of the Versus Arthritis Centre of Excellence for Rheumatoid Arthritis. He is past chairman of the Foreum (Foundation for European Rheumatology Research) Scientific Committee, leads the European Roadmap programme that is defining the research agenda for European rheumatology for the next decade and in 2019 became President of EULAR, the leading trans-national society for rheumatology across Europe. He has published >450 peer-reviewed original and review articles with an h-index of >100. He is a Fellow of the Royal Society of Edinburgh and Fellow of the Academy of Medical Sciences. He was made CBE in January 2019 by HM Queen Elizabeth II.
Challenging Cases in Rheumatoid Arthritis
Friday, November 15, 2024
12:20 PM – 12:55 PM Eastern Time
Disclosure(s): AbbVie: Consultant (Ongoing); Amgen: Consultant (Ongoing); AstraZeneca: Consultant (Ongoing); Bristol Myers Squibb: Consultant (Ongoing), Grant/Research Support (Ongoing); Cabaletta: Consultant (Ongoing), Stock options or bond holdings in a for-profit corporation or self-directed pension plan (Ongoing); Causeway Therapeutics: Consultant (Ongoing), Stock options or bond holdings in a for-profit corporation or self-directed pension plan (Ongoing); Compugen: Consultant (Ongoing), Stock options or bond holdings in a for-profit corporation or self-directed pension plan (Ongoing); Dextera: Stock options or bond holdings in a for-profit corporation or self-directed pension plan (Ongoing); Eli Lilly: Consultant (Ongoing), Grant/Research Support (Ongoing); Janssen: Consultant (Ongoing), Grant/Research Support (Ongoing); Moonlake: Consultant (Ongoing); NHS GGC: Officer or Board Member (Ongoing); Novartis: Consultant (Ongoing), Grant/Research Support (Ongoing); Pfizer: Consultant (Ongoing); Sanofi: Consultant (Ongoing); UCB: Consultant (Ongoing), Grant/Research Support (Ongoing); Versus Arthritis: Trustee Status (Ongoing)
MTP08A: Meet the Professor: Rheumatoid Arthritis
Saturday, November 16, 2024
4:30 PM – 5:30 PM Eastern Time
Disclosure(s): AbbVie: Consultant (Ongoing); Amgen: Consultant (Ongoing); AstraZeneca: Consultant (Ongoing); Bristol Myers Squibb: Consultant (Ongoing), Grant/Research Support (Ongoing); Cabaletta: Consultant (Ongoing), Stock options or bond holdings in a for-profit corporation or self-directed pension plan (Ongoing); Causeway Therapeutics: Consultant (Ongoing), Stock options or bond holdings in a for-profit corporation or self-directed pension plan (Ongoing); Compugen: Consultant (Ongoing), Stock options or bond holdings in a for-profit corporation or self-directed pension plan (Ongoing); Dextera: Stock options or bond holdings in a for-profit corporation or self-directed pension plan (Ongoing); Eli Lilly: Consultant (Ongoing), Grant/Research Support (Ongoing); Janssen: Consultant (Ongoing), Grant/Research Support (Ongoing); Moonlake: Consultant (Ongoing); NHS GGC: Officer or Board Member (Ongoing); Novartis: Consultant (Ongoing), Grant/Research Support (Ongoing); Pfizer: Consultant (Ongoing); Sanofi: Consultant (Ongoing); UCB: Consultant (Ongoing), Grant/Research Support (Ongoing); Versus Arthritis: Trustee Status (Ongoing)
MTP08B: Meet the Professor: Rheumatoid Arthritis
Sunday, November 17, 2024
7:30 AM – 8:30 AM Eastern Time
Disclosure(s): AbbVie: Consultant (Ongoing); Amgen: Consultant (Ongoing); AstraZeneca: Consultant (Ongoing); Bristol Myers Squibb: Consultant (Ongoing), Grant/Research Support (Ongoing); Cabaletta: Consultant (Ongoing), Stock options or bond holdings in a for-profit corporation or self-directed pension plan (Ongoing); Causeway Therapeutics: Consultant (Ongoing), Stock options or bond holdings in a for-profit corporation or self-directed pension plan (Ongoing); Compugen: Consultant (Ongoing), Stock options or bond holdings in a for-profit corporation or self-directed pension plan (Ongoing); Dextera: Stock options or bond holdings in a for-profit corporation or self-directed pension plan (Ongoing); Eli Lilly: Consultant (Ongoing), Grant/Research Support (Ongoing); Janssen: Consultant (Ongoing), Grant/Research Support (Ongoing); Moonlake: Consultant (Ongoing); NHS GGC: Officer or Board Member (Ongoing); Novartis: Consultant (Ongoing), Grant/Research Support (Ongoing); Pfizer: Consultant (Ongoing); Sanofi: Consultant (Ongoing); UCB: Consultant (Ongoing), Grant/Research Support (Ongoing); Versus Arthritis: Trustee Status (Ongoing)
215: UCB Product Theater – Advancements in Rheumatology
Sunday, November 17, 2024
3:30 PM – 4:15 PM Eastern Time
No financial relationships with ineligible companies to disclose
220: Achieving an Immune System RESET: The Next Act in CAR T Therapy
Monday, November 18, 2024
10:30 AM – 11:15 AM Eastern Time
No financial relationships with ineligible companies to disclose
Monday, November 18, 2024
1:15 PM – 1:30 PM Eastern Time
No financial relationships with ineligible companies to disclose